A detailed history of Euclidean Capital LLC transactions in Ngm Biopharmaceuticals Inc stock. As of the latest transaction made, Euclidean Capital LLC holds 992,168 shares of NGM stock, worth $0. This represents 0.2% of its overall portfolio holdings.

Number of Shares
992,168
Previous 992,168 -0.0%
Holding current value
$0
Previous $853,000 84.88%
% of portfolio
0.2%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$1.05 - $3.37 $257,768 - $827,314
245,494 Added 32.88%
992,168 $1.06 Million
Q4 2021

Feb 14, 2022

SELL
$17.26 - $22.02 $1.48 Million - $1.88 Million
-85,600 Reduced 10.29%
746,674 $13.2 Million
Q3 2021

Nov 15, 2021

SELL
$20.15 - $26.19 $13.3 Million - $17.3 Million
-661,075 Reduced 44.27%
832,274 $17.5 Million
Q1 2021

May 17, 2021

SELL
$24.99 - $31.93 $14.8 Million - $18.8 Million
-590,253 Reduced 28.33%
1,493,349 $43.4 Million
Q4 2020

Feb 12, 2021

BUY
$16.21 - $31.44 $33.8 Million - $65.5 Million
2,083,602 New
2,083,602 $63.1 Million

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Euclidean Capital LLC Portfolio

Follow Euclidean Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Euclidean Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Euclidean Capital LLC with notifications on news.